Artículo
Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort
Autor/es | Salto Alejandre, Sonsoles
Palacios-Baena, Zaira R. Arribas, José Ramón Berenguer, Juan Carratalà, Jordi Jarrín, Inmaculada Ryan, Pablo Miguel Montero, Marta de Rodríguez-Baño, Jesús Pachón Díaz, Jerónimo |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2022 |
Fecha de depósito | 2022-09-27 |
Publicado en |
|
Resumen | Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its
in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was ... Background: Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-β treatment in patients admitted with COVID-19 during the first wave of the pandemic. Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult pa tients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-β, defined as early if started ≤ 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-β therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis. Results: Overall, 683 patients (17.9%) received early interferon-β therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-β was 1.03 (95% CI, 0.82–1.30) in the overall cohort, 0.96 (0.82–1.13) in the PS-matched subcohort, and 0.89 (0.60–1.32) when interferon-β treatment was analyzed as a time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-β therapy after hospital admission did not show an association with lower mortality. Whether interferon-β might be useful in the earlier stages of the disease or specific subgroups of patients requires further research. |
Cita | Salto Alejandre, S., Palacios-Baena, Z.R., Arribas, J.R., Berenguer, J., Carratalà, J., Jarrín, I.,...,Pachón Díaz, J. (2022). Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. Biomedicine & pharmacotherapy, 146, 1-10. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Impact of early.pdf | 796.7Kb | [PDF] | Ver/ | |